BCM
HZNP

BCK Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

BCK Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-287,868
Closed -$33.3M – 112
2023
Q3 		$33.3M Sell
287,868
-58,877
-17% -$6.33M 16.94% 2
2023
Q2 		$35.7M Buy
346,745
+272,467
+367% +$28.7M 27.22% 1
2023
Q1 		$8.11M Buy
74,278
+60,371
+434% +$6.67M 7.05% 5
2022
Q4 		$1.58M Buy
+13,907
New +$1.16M 1.63% 18

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

BCK Capital Management's HZNP Position: Q4 2023 in Review

BCK Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 287,868 shares — an estimated $33.3M sold.

BCK Capital Management first reported a position in HZNP in Q4 2022 and held it in 4 quarters. The position peaked at $35.7M in Q2 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • BCK Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • BCK Capital Management sold 287,868 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $33.3M.
  • BCK Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 4 quarters.
  • BCK Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $35.7M in Q2 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on BCK Capital Management's 13F filing for Q4 2023, filed 6 Feb 2024.